Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

MPC Versus PID for Closed Loop Insulin Delivery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02438670
Recruitment Status : Completed
First Posted : May 8, 2015
Last Update Posted : July 22, 2016
Sponsor:
Collaborator:
University of California, Santa Barbara
Information provided by (Responsible Party):
Sansum Diabetes Research Institute

Tracking Information
First Submitted Date  ICMJE May 6, 2015
First Posted Date  ICMJE May 8, 2015
Last Update Posted Date July 22, 2016
Study Start Date  ICMJE May 2015
Actual Primary Completion Date September 2015   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: May 7, 2015)
Time spent in safe blood glucose range [ Time Frame: 27.5-hours ]
The percentage of time spent in safe blood glucose range of 70-180 mg/dl, comparing MPC, PID and the 24-hour period of Open-Loop Care just prior to each study session. More time spent inside the desired range will be considered successful.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: May 7, 2015)
Glucose level extremes and need for outside intervention [ Time Frame: 27.5-hours ]
The secondary endpoint measures glucose extremes (the time spent in the hypoglycemic range <70 mg/dl, time spent in the hyperglycemic range >180 mg/dl) and the need for outside intervention to prevent hypoglycemia or hyperglycemia comparing MPC, PID and the 24-hour period of Open-Loop Care just prior to each study session. Interventions would be insulin injections or oral carbohydrates given to the subject by the physician, as well as alerts from the health monitoring system. No need for physician intervention will be considered a successful outcome.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE MPC Versus PID for Closed Loop Insulin Delivery
Official Title  ICMJE Use of a PID (Proportional-Integral-Derivative) Controller Versus an MPC (Model Predictive Control) Controller Algorithm and Health Monitoring System (HMS) for Closed-Loop Insulin Delivery
Brief Summary The goal of this proposed study is to compare use of a PID (Proportional-Integral-Derivative) controller versus an MPC (Model Predictive Control) controller algorithm in an artificial pancreas system, all other components and study design being equal. The study design, power calculation and endpoints were developed based on the results of an initial feasibility study (ClinicalTrials.gov Identifier: NCT01987206) that has already been completed.
Detailed Description This randomized crossover study consists of an evaluation of either type of control algorithm (MPC or PID) as a part of the Artificial Pancreas (AP) device during two periods of 27.5-hour closed-loop control in a minimally supervised setting (outpatient research area at the William Sansum Diabetes Center, Santa Barbara, CA) separated by a minimum of 5 days and a maximum of 2 weeks. The 27.5-hour period includes: 2 announced meals (dinner and breakfast of 65g and 50g CHO respectively) preceded with a dose of rapid-acting insulin equivalent to 100% bolus based on each subject's Insulin to Carbohydrate (I:C) ratio and 1 unannounced meal (lunch of 65g carbohydrates, same meal content as dinner); complete night from 12:00 am to 7:00 am. The goal is to demonstrate that the AP device is able to maintain the subject blood glucose within a safe range at all times.
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Type 1 Diabetes Mellitus
Intervention  ICMJE
  • Device: PID control algorithm
  • Device: MPC control algorithm
Study Arms  ICMJE
  • No Intervention: Open-Loop Care
    The subjects Open-Loop Care for the 24-hour period prior to each study sessions assessed for time in the target range 70-180 mg/dL, and frequency of hypoglycemia and hyperglycemia as assessed by CGM.
  • Experimental: PID algorithm with HMS

    Subjects will be treated with closed-loop care for 27.5h using a proportional-integral-derivative (PID) control algorithm, incorporating a personalized model of glucose-insulin dynamics.

    The health monitoring system (HMS) predicts impending hypoglycemia, and will be used in both experimental arms as an important safety feature of the device.

    Intervention: Device: PID control algorithm
  • Experimental: MPC algorithm with HMS

    Subjects will be treated with closed-loop care for 27.5h using a model predictive control (MPC) control algorithm with HMS, using the identical model as in the first experimental arm.

    The health monitoring system (HMS) predicts impending hypoglycemia, and will be used in both experimental arms as an important safety feature of the device.

    Intervention: Device: MPC control algorithm
Publications * Pinsker JE, Lee JB, Dassau E, Seborg DE, Bradley PK, Gondhalekar R, Bevier WC, Huyett L, Zisser HC, Doyle FJ 3rd. Randomized Crossover Comparison of Personalized MPC and PID Control Algorithms for the Artificial Pancreas. Diabetes Care. 2016 Jul;39(7):1135-42. doi: 10.2337/dc15-2344. Epub 2016 Jun 11.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: May 7, 2015)
20
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE September 2015
Actual Primary Completion Date September 2015   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Clinical diagnosis of type 1 diabetes for at least one year and using an insulin pump for at least 6 months with commercially available rapid acting insulin.
  • The diagnosis of type 1 diabetes is based on the investigator's judgment; C peptide level and antibody determinations are not needed.
  • Age 21 to 65 years
  • For females, not currently known to be pregnant or nursing
  • HbA1c between 5 to 10%, as measured with DCA2000 or equivalent device
  • Willing to perform the calibration of the study CGMs using a fingerstick only and willing to follow instructions for insulin pump and CGM wear.
  • Willing to use the study CGM and study insulin pump during closed-loop.
  • Able to and agrees to avoid the following medication starting 24 hours before sensor wear through completion of the close loop study visit: acetaminophen, prednisone, and pseudoephedrine.
  • An understanding of and willingness to follow the protocol and sign the informed consent.

Exclusion Criteria:

  • Exhibit hypoglycemia unawareness.
  • Indications of cardiac arrhythmia.
  • Pregnancy (as determined by a positive blood pregnancy test performed in females of childbearing capacity during screening visit and urine test at time of admission for in-patient visit) or nursing mother.
  • Diabetic ketoacidosis in the past 6 months prior to enrollment requiring emergency room visit or hospitalization
  • Severe hypoglycemia resulting in seizure or loss of consciousness in the 12 months prior to enrollment
  • Current treatment for a seizure disorder; Subjects with a history of seizures may be included in the study if they receive written clearance from their neurologist
  • Active infection
  • A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol such as cognitive deficit.
  • Mental incapacity, unwillingness or language barriers precluding adequate understanding or co-operation, including subjects not able to read or write.
  • Coronary artery disease or heart failure.
  • Subjects with a history of coronary artery disease may be included in the study if they receive written clearance from their cardiologist
  • Presence of a known adrenal disorder
  • Active gastroparesis
  • If on antihypertensive, thyroid, anti-depressant or lipid lowering medication, lack of stability on the medication for the past 2 months prior to enrollment in the study
  • Uncontrolled thyroid disease; Adequately treated thyroid disease and celiac disease do not exclude subjects from enrollment
  • Abuse of alcohol
  • Current use of a beta blocker medication
  • Laboratory results:

Hematocrit < 30% or >55% A1C > 10% Abnormal liver or renal function (Transaminase >2 times the upper limit of normal, Creatinine> 1.5 mg/dL) Labs drawn at screening visit or within one month prior to screening (for other purposes) will suffice for enrollment purposes related to hematocrit

  • Subject has skin conditions that, in the determination of the investigator, would preclude wearing the study devices (infusion set and sensor), in the abdomen. Examples include but are not limited to: psoriasis, burns, scaring, eczema, tattoos, and significant hypertrophy at sites of device wear; any known allergy to medical adhesives.
  • Currently on long-term treatment using prednisone. If subject had been on short term treatment of prednisone, defer enrollment until underlying condition and prednisone treatment have resolved.
  • Allergy to study drug, food or other study material.
  • Clinically significant screening ECG, physical examination, laboratory test, or vital sign abnormality.
  • Exposure to any investigational drug within 30 days.
  • History of malignancy within the 5 years before screening (other than basal cell carcinoma).
  • Currently smoking or discontinued smoking (including cigarettes, cigars, pipes) over the past 6 months.
  • Current participation in another investigational trial.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 21 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02438670
Other Study ID Numbers  ICMJE 13-68u
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Sansum Diabetes Research Institute
Study Sponsor  ICMJE Sansum Diabetes Research Institute
Collaborators  ICMJE University of California, Santa Barbara
Investigators  ICMJE
Principal Investigator: Jordan E Pinsker, MD Sansum Diabetes Research Institute
Principal Investigator: Eyal Dassau, PhD University of California, Santa Barbara
Principal Investigator: Francis J Doyle III, PhD University of California, Santa Barbara
PRS Account Sansum Diabetes Research Institute
Verification Date July 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP